Indonesia's First Blood Plasma Fractionation Plant to Boost Healthcare Independence

Strategic Investment for National Health Security

Indonesia is on the verge of a significant healthcare breakthrough with the upcoming launch of its first blood plasma fractionation plant in 2026. Developed by PT SK Plasma Core Indonesia, a strategic joint venture between South Korean company SK Plasma and Indonesia Investment Authority (INA), this facility represents a major step towards achieving national self-sufficiency in plasma-derived medicinal products (PODP).

Addressing Current Challenges

Currently, Indonesia faces a critical situation where over 200,000 liters of plasma are wasted annually due to the lack of domestic fractionation capabilities. This results in the country being 100% dependent on imports for critical plasma products such as immunoglobulin, albumin, and factor VIII. The new facility, located in Karawang International Industrial City (KIIC) across 5 hectares, will have the capacity to process 600,000 liters of plasma per year, effectively addressing this shortage.

Technological and Economic Impact

The plant adopts operational systems and technology from SK Plasma's existing facility in Andong, Korea, which has been supplying plasma-derived products to 17-20 countries since 2018. This technology transfer includes not just equipment but also knowledge transfer and capacity building for Indonesian workers. The project has already created jobs during the construction phase and will continue to do so during operations.

Product Portfolio and Health Impact

The facility will produce essential plasma-derived products including:

1. Immunoglobulin for treating primary immunodeficiencies and autoimmune diseases
2. Albumin for managing conditions like hypoalbuminemia and hemorrhagic shock
3. Factor VIII for hemophilia A treatment

These products are particularly crucial during health crises, as evidenced during the COVID-19 pandemic when global supply chains were severely disrupted.

Future Prospects

The successful implementation of this project is expected to:

1. Enhance national health security by reducing import dependency
2. Create employment opportunities in both construction and operational phases
3. Position Indonesia among the limited group of countries with plasma fractionation capabilities
4. Potentially enable future exports of plasma-derived products

As Indonesia moves towards healthcare self-sufficiency, this project marks a significant milestone in the country's healthcare development strategy.